Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- SABCS 2017: Recommendations From Dr. Lee Schwartzberg: Early Breast Cancer
- Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy vs Trastuzumab Plus Pertuzumab in HER2+ Breast Cancer
- Neratinib After Trastuzumab-Based Adjuvant Therapy Improves Invasive DFS in HER2+ Breast Cancer
- Single-Dose NEPA Is Noninferior to 3-Day Oral Aprepitant/Granisetron for Preventing CINV
- Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology
- Tracking Aromatase Inhibitor Resistance With ctDNA Analysis in Metastatic Breast Cancer
- Current Approaches to Managing CINV
- Axillary Dissection vs No Axillary Dissection and 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis
- Advances in CDK 4/6 Inhibitor Use For Metastatic Breast Cancer From ESMO 2017
- New Data on Triple Negative Breast Cancer From ESMO 2017